HIK.L Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 17:35):

Stats
Tagesvolumen	14.05M
Durchschnittsvolumen	622 167
Marktkapitalisierung	4.35B
EPS	£0 ( 2024-02-22 )
Last Dividend	£25.00 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	28.82
ATR14	£1.822 (0.09%)

Volumen Korrelation

Lang: 0.20 (neutral)

Kurz: -0.92 (very strong negative)

Signal:(46.114) Neutral

Hikma Pharmaceuticals PLC Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Hikma Pharmaceuticals PLC Korrelation - Währung/Rohstoff

-0.61
( weak negative )

-0.38
( neutral )

0.50
( neutral )

0.21
( neutral )

0.25
( neutral )

-0.26
( neutral )

Hikma Pharmaceuticals PLC Finanzdaten

Annual	2023
Umsatz:	£2.88B
Bruttogewinn:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
Umsatz:	£2.88B
Bruttogewinn:	£1.39B (48.35 %)
EPS:	£0.860

FY	2023
Umsatz:	£0
Bruttogewinn:	£0 (0.00 %)
EPS:	£0

FY	2022
Umsatz:	£2.52B
Bruttogewinn:	£1.27B (50.26 %)
EPS:	£0.840

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£16.00 (N/A)	£0 (N/A)	£29.52 (N/A)	£0 (N/A)	£25.00 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Hikma Pharmaceuticals PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 9.93 - good (99.32%) | Divividend Growth Potential Score: 3.83 - Decrease likely (23.40%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£0.500	2006-04-26
Last Dividend	£25.00	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	36	--
Total Paid Out	£347.38	--
Avg. Dividend % Per Year	1.60%	--
Score	4.06	--
Div. Sustainability Score	9.93
Div.Growth Potential Score	3.83
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-06-25)

£25.96 Estimate 7.54 %

Dividend Stability

0.30 Poor

Dividend Score

4.06

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.40	1.92%
2019	£34.00	1.99%
2020	£36.22	1.82%
2021	£37.70	1.47%
2022	£42.00	1.92%
2023	£54.52	3.36%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
WRKS.L	Ex Dividend Junior	2023-10-05	Sporadic	6	1.18%
NCYF.L	Dividend King	2023-07-27	Quarterly	20	4.98%
EDV.L	Dividend Knight	2023-08-31	Semi-Annually	4	2.42%
SPE.L	Dividend Junior	2023-06-08	Annually	7	0.30%
ITV.L	Dividend Knight	2023-10-19	Annually	21	2.25%
BRSC.L	Dividend Knight	2023-05-18	Semi-Annually	47	1.21%
PHAR.L	Dividend Junior	2023-06-15	Sporadic	12	1.15%
FNTL.L	Dividend Knight	2023-09-28	Semi-Annually	7	1.21%
AAIF.L	Dividend King	2023-07-27	Quarterly	19	2.67%
TFGS.L	No Dividend Player	2023-08-02	Annually	7	0.01%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0661	1.500	8.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0406	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.0866	1.500	-0.149	-0.223	[0.1 - 1]
payoutRatioTTM	0.721	-1.000	2.79	-2.79	[0 - 1]
currentRatioTTM	1.568	0.800	7.16	5.73	[1 - 3]
quickRatioTTM	0.831	0.800	9.82	7.85	[0.8 - 2.5]
cashRatioTTM	0.153	1.500	-0.261	-0.391	[0.2 - 2]
debtRatioTTM	0.254	-1.500	5.76	-8.64	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.939	2.00	9.03	10.00	[0 - 20]
debtEquityRatioTTM	0.542	-1.500	7.83	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.489	1.000	5.18	5.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.215	1.000	7.69	7.69	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.510	1.000	8.28	8.28	[0.2 - 2]
assetTurnoverTTM	0.614	0.800	9.24	7.39	[0.5 - 2]
Total Score				9.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	29.31	1.000	7.14	0	[1 - 100]
returnOnEquityTTM	0.0866	2.50	-0.0956	-0.223	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.939	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.15	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.68	2.00	9.11	10.00	[0 - 30]
payoutRatioTTM	0.721	1.500	2.79	-2.79	[0 - 1]
pegRatioTTM	-119.14	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.211	1.000	7.21	0	[0.1 - 0.5]
Total Score				3.83

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.